Compugen Announces Positive In-Vivo Results for Therapeutic Peptide Candidate for Immune Related Diseases
News Jul 10, 2008
Compugen Ltd. has announced positive results from a recently completed in vivo study of CGEN-25007, a novel peptide antagonist of the gp96 protein.
The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.
CGEN-25007, which has been shown to bind to recombinant gp96 in a dose dependent manner, was initially predicted using the Company’s previously announced DAC blockers platform, which was designed to predict peptides that block proteins of interest from achieving certain disease-associated conformations.
Using an animal model of endotoxemia, a condition in which there is a substantial increase in the levels of inflammatory cytokines and chemokines in serum, CGEN-25007 was shown to exhibit a profound and dose-dependent anti-inflammatory activity.
In this study, the novel peptide was administered following the introduction of lipopolysaccharide (LPS), a bacterial substance that induces a strong response in the animal immune system leading to systemic inflammation.
The administration of CGEN-25007 resulted in a decrease of approximately 50% in the serum levels of inflammatory cytokines and chemokines, including tumor necrosis factor alpha (TNF-a), IL-6, interferon-gamma (IFN-?), MIP-1a and MIP-2.
In addition, in ex-vivo experiments CGEN-25007 was found to strongly inhibit the secretion of inflammatory cytokines from human peripheral blood mononuclear cells (PBMCs) which had been challenged with LPS, staphylococcus epidermidis or anti-CD3 antibody, compounds known to activate the human immune system through different receptors.
PBMCs triggered with these compounds and treated with CGEN-25007 exhibited more than 80% inhibition of secretion of cytokines, including TNFa, IL-1ß, IL-6, IL-8, IL-12 and MIP-1a. In addition, CGEN-25007 had only a 20% inhibitory effect on the secretion of GM-CSF and no effect on the secretion of IL-2, suggesting selectivity in the action of this peptide.
These results support the potential use of this peptide as a novel approach for the treatment of many immune related diseases, including sepsis, autoimmune disorders, cardiovascular diseases and acute transplant rejection.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018